Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NYSE:MYOV

Myovant Sciences (MYOV) Stock Price, News & Analysis

Myovant Sciences logo

About Myovant Sciences Stock (NYSE:MYOV)

Key Stats

Today's Range
$26.98
$27.00
50-Day Range
$26.88
$26.99
52-Week Range
$7.67
$27.06
Volume
2.26 million shs
Average Volume
1.17 million shs
Market Capitalization
$2.62 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.

Receive MYOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Myovant Sciences and its competitors with MarketBeat's FREE daily newsletter.

MYOV Stock News Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
See More Headlines

MYOV Stock Analysis - Frequently Asked Questions

Myovant Sciences Ltd. (NYSE:MYOV) issued its quarterly earnings results on Tuesday, October, 26th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.11. The company earned $77.90 million during the quarter, compared to analyst estimates of $72.67 million.

Myovant Sciences (MYOV) raised $176 million in an initial public offering (IPO) on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays served as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Myovant Sciences investors own include NVIDIA (NVDA), Meta Platforms (META), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

Company Calendar

Last Earnings
10/26/2021
Today
12/25/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Previous Symbol
NASDAQ:MYOV
Fax
N/A
Employees
407
Year Founded
N/A

Profitability

Net Income
$-205,980,000.00
Pretax Margin
-42.81%

Debt

Sales & Book Value

Annual Sales
$230.97 million
Book Value
($5.04) per share

Miscellaneous

Free Float
95,388,000
Market Cap
$2.62 billion
Optionable
Not Optionable
Beta
2.17
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

This page (NYSE:MYOV) was last updated on 12/25/2024 by MarketBeat.com Staff
From Our Partners